Society of Hematologic Oncology Annual Meeting (SOHO) | Conference

Ivosidenib/Azacitidine Combo Elicits Survival Benefit Over Placebo in IDH1-Mutated AML

September 29th 2022

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

Investigators Set Sights on Optimizing CAR T-Cell Therapy in Lymphoma

September 4th 2022

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Future of MPN Research, Treatment Revolves Around Addressing ‘A Main Problem’

September 11th 2021

Although there are several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Racial, Social Disparities Linked With T-Cell Lymphoma Outcomes

September 11th 2021

Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

Ruxolitinib Represents a Key Clinical Tool in Polycythemia Vera Paradigm

September 11th 2021

The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of patients with polycythemia vera and plays an especially important role in adult patients who have had an inadequate response to hydroxyurea.

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Dr. Danilov on the Need to Identify Novel Pathways in CLL

September 11th 2021

Alexey V. Danilov, MD, PhD, discusses the need to identify novel pathways for targeted therapy in chronic lymphocytic leukemia.

Dr. Kahl on the Potential for Frontline BTK Inhibitor Combinations in MCL

September 10th 2021

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

September 10th 2021

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

Rituximab-Bendamustine Combo Induces Superior Outcomes Over Other Regimens in Waldenström Macroglobulinemia

September 10th 2021

Treatment with fixed-duration rituximab plus the chemotherapy bendamustine was associated with more favorable outcomes than the triplet of dexamethasone, rituximab, and cyclophosphamide, as well as bortezomib, dexamethasone, and rituximab in patients with treatment-naïve Waldenström macroglobulinemia.

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma

September 10th 2021

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

Challenges Remain in Treatment of Accelerated Phase Myeloproliferative Neoplasms

September 10th 2021

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

September 10th 2021

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

TP53 and IGHV Status Retain Utility as Prognostic Markers in CLL

September 9th 2021

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

Noncovalent BTK Inhibitors, CAR T-Cell Therapy Generate Excitement in CLL

September 9th 2021

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Controlling Infections Could Be Key to Improving Survival in CLL

September 9th 2021

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera

September 9th 2021

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

September 9th 2021

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Treatment Strategies Utilizing New Agents and Existing Therapies Can Improve Outcomes in Myelofibrosis

September 9th 2021

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Future of PV Treatments Centers Around More Tailored Approaches

September 9th 2021

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.